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HMGA1 (high mobility group A1) is a nonhistone architectural chromosomal protein that
functions mainly as a dynamic regulator of chromatin structure and gene transcription.
As such, HMGA1 is involved in a variety of fundamental cellular processes, including
gene expression, epigenetic regulation, cell differentiation and proliferation, as well as
DNA repair. In the last years, many reports have demonstrated a role of HMGA1 in the
transcriptional regulation of several genes implicated in glucose homeostasis. Initially, it
was proved that HMGA1 is essential for normal expression of the insulin receptor (INSR),
a critical link in insulin action and glucose homeostasis. Later, it was demonstrated that
HMGA1 is also a downstream nuclear target of the INSR signaling pathway, representing
a novel mediator of insulin action and function at this level. Moreover, other observations
have indicated the role of HMGA1 as a positive modulator of the Forkhead box protein
O1 (FoxO1), a master regulatory factor for gluconeogenesis and glycogenolysis, as well
as a positive regulator of the expression of insulin and of a series of circulating proteins
that are involved in glucose counterregulation, such as the insulin growth factor binding
protein 1 (IGFBP1), and the retinol binding protein 4 (RBP4). Thus, several lines of
evidence underscore the importance of HMGA1 in the regulation of glucose production
and disposal. Consistently, lack of HMGA1 causes insulin resistance and diabetes in
humans and mice, while variations in the HMGA1 gene are associated with the risk
of type 2 diabetes and metabolic syndrome, two highly prevalent diseases that share
insulin resistance as a common pathogenetic mechanism. This review intends to give an
overview about our current knowledge on the role of HMGA1 in glucose metabolism.
Although research in this field is ongoing, many aspects still remain elusive. Future
directions to improve our insights into the pathophysiology of glucose homeostasis
may include epigenetic studies and the use of “omics” strategies. We believe that a
more comprehensive understanding of HMGA1 and its networks may reveal interesting
molecular links between glucose metabolism and other biological processes, such as
cell proliferation and differentiation.
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INTRODUCTION
Glucose homeostasis is essential for life, and its maintenance is
ensured through evolutionarily conserved regulatory
mechanisms, that implicate complex and fine-tuned interplays
between a variety of organs, tissues, hormones, receptors,
nutrients, sensors, enzymes, and other molecules that may act
locally and systemically (1, 2). In a physiological setting, the
earliest mechanisms regulating postprandial hyperglycemia
involve: (i) the readily releasable pool of insulin granules; (ii)
the membrane translocation of glucose transporters in insulin-
target tissues; (iii) post-translational regulatory mechanisms,
mostly based upon post-translational modifications (i.e.,
phosphorylation), which affect enzyme functions that are
implicated in carbohydrate metabolism, glucose homeostasis
and disposal. Instead, during fasting conditions, when blood
glucose levels are low, glucagon secretion increases to activate
glycogenolysis and gluconeogenesis, thereby promoting hepatic
glucose production to maintain fasting euglycemia. On a longer
time-scale, instead, other effective mechanisms take place, which
entail the transcriptional activation of genes and gene networks
that function to control glucose homeostasis. In this context,
glucose and insulin may regulate several “metabolic” genes by
modulating the activity of nuclear factors toward their target
genes (3). For example, it has been shown that glucose influences
insulin gene transcription by inducing the phosphorylation of
the glucose-sensitive PDX-1 transcription factor in pancreatic
beta cells (4), while insulin can inhibit genes by triggering the
phosphorylation of the forkhead box protein O1 (FoxO1), and
its consequent relocation from the nucleus to the cytoplasm
(5, 6). However, although in the last decades many studies have
contributed to a better understanding of the transcriptional
regulation of glucose metabolism, the role and interplay of
several nuclear transcription factors in this scenario need further
elucidation.
The high mobility group A1 (HMGA1) protein (also
formerly known as HMGI/Y) is an architectural transcription
factor involved in global chromatin remodeling. By interacting
with both DNA and transcription factors, it regulates many
fundamental biological processes, ranging from embryonic
development to cell proliferation and differentiation, apoptosis,
senescence and repair of DNA (7–13). Before the last two
decades, HMGA1 has been mainly studied for its role in
oncology, and to a lesser extent, in inflammation (9, 10, 14). Later,
as part of investigations aimed at understanding the molecular
basis of regulation of insulin receptor (INSR) gene expression,
HMGA1 has emerged as a crucial factor in the transcriptional
regulation of the INSR gene, and other genes relevant to
glucose metabolism (15–18). Within this metabolic context,
novel HMGA1 molecular partners have been identified, and
their functional interplay investigated, while, in the meantime,
HMGA1 gene variants have been identified as reliably linked
to both type 2 diabetes mellitus, and the metabolic syndrome
(19–21).
The purpose of this review is to summarize current
information on the structural and functional characteristics of
HMGA1, and its role in the transcriptional regulation of the
metabolic genes so far investigated. In this scenario, HMGA1
emerges as a crucial factor in the regulation of glucose production
and disposal. Also, a recently recognized role of theHMGA1 gene
locus as a favored locus for susceptibility to insulin resistance and
metabolic diseases is discussed, while future research directions
are proposed to gain further insights into the links between
HMGA1 and the pathophysiology of glucose metabolism and
homeostasis.
GENERAL CHARACTERISTICS OF HMGA1
Gene Structure, Transcriptional
Regulation, and Protein Synthesis
In humans, the HMGA1 gene is located on chromosome 6p21
(NC_000006.12), and it is well conserved among species (22,
23). Cloning and characterization of this gene reveal a very
complex genomic organization, which includes a 5′ untranslated
region (UTR) that undergoes alternative splicing, a coding region
distributed on four exons, and a large 3′UTR (Figure 1). As
for other genes, it is plausible that the size of the 5′UTR
may influence the stability and translation efficacy of HMGA1
transcripts (24). The regulatory region of the HMGA1 gene is
highly GC-rich as a whole and lacks TATA and CAAT box
sequences; also, it includes at least two transcription start sites
with different promoter/enhancer regions (22, 25, 26), as it occurs
for genes that are regulated without the preferential selection of
any specific start site. However, a privileged utilization of start
site 2 has been demonstrated in certain cell types and under
certain experimental conditions (26), thus indicating a tight gene
regulation that results in the transcription of specific mRNAs in
response to different stimuli. In addition, it has been reported
that the human HMGA1 gene displays a basal transcriptional
activity mainly controlled by the specificity protein 1 (Sp1) and
the activator protein 1 (AP1) transcription factors, both of which
stimulate HMGA1 gene expression from the transcription start
site 1 and the transcription start site 2, respectively (27).
A functional c-Myc-Max consensus DNA binding site was
identified in the HMGA1 promoter and, consistent with this,
the oncoprotein c-Myc and its protein partner Max bind to
this site and activate HMGA1 gene transcription (28). Also,
the HMGA1 promoter is activated by the transforming growth
factor-β1 (TGF-β1) (29). Recently, we identified an octamer
motif ATGCAAAT at the beginning of exon 1, where the
octamer transcription factors Oct-1 and Oct-2 exert a differential
regulation of HMGA1 gene transcription, and demonstrated
that, by binding its own promoter, HMGA1 can contribute to
its transactivation by Oct-2 (30), thus supporting a previous
observation about the role of HMGA1 in an auto-regulatory
circuit (31). More recently, it has been reported that G9a, an
activator of gene transcription and a histone methyltransferase,
positively regulates the expression of theHMGA1 gene in hepatic
cells (32).
The complexity of the HMGA1 gene structure and
transcriptional regulation results in the generation of a
series of mRNA isoforms that are largely derived from an
extensive alternative splicing in the 5′UTR (Figure 1). Instead,
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FIGURE 1 | Schematic representation of human HMGA1 gene, transcripts, and protein isoforms. Exons are indicated by colored, numbered boxes. Main mRNA
isoforms for both HMGA1a and HMGA1b are illustrated. Aminoacid sequence with the three functional AT-hook domains of both isoform proteins are reported.
the coding sequence undergoes only one differential splicing that
produces the two protein isoforms, HMGA1a, consisting of 107
aminoacids, and HMGA1b, which lacks 11 aminoacids at the end
of exon 5 (33) (Figure 1). Both protein isoforms contain three
AT-hook DNA binding domains, a protein-protein interaction
domain, which overlaps with the second AT-hook and includes
the aminoacid sequence up to the third AT- hook, and a highly
negative and constitutively phosphorylated C-terminal tail (11).
Each DNA binding domain includes the core peptide motif
Pro-Arg-Gly-Arg-Pro (P-R-G-R-P) (Figure 1), through which
HMGA1 preferentially interacts with the minor groove of AT-
rich DNA sequences (34, 35). Although all three AT-hook motifs
synergize during target recognition, the first two AT-hooks
contribute to the majority of HMGA1 affinity for DNA (36). The
two different HMGA1 isoforms may have different biological
functions, as indicated by studies in MCF-7 breast epithelial cells,
where HMGA1b forced expression confers a more aggressive
neoplastic phenotype than HMGA1a (37). However, in the
context of other cell lines or of other biological processes,
including metabolism, more investigations are needed to deepen
this issue.
Being among the most abundant non-histone, chromatin-
associated protein, HMGA1 has been shown to cooperate with
other nuclear proteins, including the chaperone nucleophosmin
(38), and to play a role in the chromatin organization by an
interplay with histones (39, 40). Interactions of HMGA1 with
transcription factors will be later discussed in the “DNA, protein
and RNA interactions” paragraph.
Post-transcriptional Regulation
The functional activity of HMGA1 relies on a complex and
fine regulation of its own expression. This includes a series of
regulatory elements that act within the 3′UTR HMGA1 mRNA
(41). In addition, recent studies indicate that many microRNAs
could bind the HMGA1 3′UTR mRNA, causing its degradation
or inhibiting its translation (42). Down-regulation of some of
these microRNAs—miR15, miR-16, miR26, miR-196a-2, and let-
7—have been described to cause increased levels of HMGA1 in
pituitary adenomas (42). Interestingly, some of the samemiRNAs
involved in tumorigenesis also play a role in metabolism. For
example, miR-26a has been shown to target key regulators of
insulin signaling and glucose metabolism in the liver, while its
impairment is associated with hepatic oncogenesis and metabolic
disorders (43).
Another peculiar mechanism of HMGA1 post-transcriptional
regulation refers to the role of processed pseudogenes as
potential regulators of mRNA stability/degradation (44).
Processed pseudogenes are non-functional copies of normal
genes generated by a process of mRNA retrotransposition.
Compared with homologous normal genes, they lack introns
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and contain single nucleotide substitutions, deletions, insertions,
and residues of poly (A) tails (45, 46). Human genome includes
thousands of pseudogenes, accumulated during evolution
(45, 46). However, although our actual knowledge about the
real biological role of pseudogenes is still limited, increasing
evidences exist, supporting a functional significance for these
macromolecules (47). So far, eight HMGA1 pseudogenes have
been described (48). Some of them act on the stability of HMGA1
mRNA or prevent miRNAs from targeting HMGA1 mRNA,
thereby behaving as competing endogenous RNAs (ceRNAs).
The RNA encoded by one of them, the HMGA1-p pseudogene,
by effectively competing for the trans-acting cytoplasmic protein
αCP1, accelerates the degradation of mRNA from the homolog
normal gene, thereby reducing the longevity of HMGA1
mRNA transcript (44). Some pseudogenes display aminoacid
sobstitutions at the level of specific aminoacid residues that in the
native HMGA1 are subjected to post-translational modifications
involved in the modulation of HMGA1’s activities. An intriguing
possibility is that, if expressed, these proteins could compete
with the native HMGA1, escaping the modulatory effects of
these post-translational modifications that strongly impact on
HMGA1 ability for chromatin remodeling and protein-protein
interactions (48).
Post-translational Modifications (PTMs)
A variety of extracellular and intracellular signals can induce
different PTMs on HMGA1 protein, which influence its ability to
interact with either DNA or proteins, thereby affecting HMGA1
nuclear function (8, 49). PTMs include phosphorylation,
methylation, and acetylation (8, 12, 49, 50). Generally, increased
level of HMGA1 phosphorylation reduces DNA-binding affinity
and transcriptional activation, and this status correlates with an
elevated residence time of the HMGA1a isoform in the repressed
inactive heterochromatin, rather than in the active euchromatin
(35). In detail, phosphorylation can affect different serine (Ser)
and threonine (Thr) residues. The phosphorylation at Thr-52
and Thr-77 by the cell-cycle dependent kinase cdc2 results in
decreased binding of HMGA1a to DNA (51, 52). The same
effect is produced following the phosphorylation of HMGA1a
at Ser-43 and Ser-63 by the protein kinase C (PKC) pathway
(53). The acidic C-terminal tail of HMGA1 is constitutively
phosphorylated. At this level, the protein kinase CK2 catalyzes
the phosphorylation of Ser-98, Ser-101, and Ser-102 of HMGA1a
(54), while it has been demonstrated that phosphorylation of
the C-terminal tail has structural consequences on HMGA1
compactness (55). HMGA1 is also susceptible to acetylation on
several lysine residues (49). It has been reported that acetylation
by the histone acetyltransferases CBP (CREB-binding protein)
and p300/CBP associated factor (PCAF)/GCN5 have a role in the
kinetics of enhanceosomes assembly/disassembly. Acetylation
at Lys-64, by CBP, destabilizes the enhanceosome formation
on the human interferon beta (IFN-beta) gene, leading to
transcriptional inhibition of this gene; on the contrary, PCAF-
induced acetylation at Lys-70 increased the transcription of
the IFN-beta gene through enhanceosome stabilization (56).
HMGA1 is also methylated at several residues located exclusively
within the AT-hook motifs. Although the significance of this
type of PTM is still largely unknown, methylation at the AT-
hookmotifs indicate a potential role formethylation in regulating
HMGA1-DNA binding activity (12, 49, 57–59).
Tissue Expression of HMGA1
HMGA1 is highly expressed during embryogenesis, suggesting
its critical role during the embryonic development (60). It is
also highly expressed in adult stem cells, including intestinal
and hematopoietic stem cells (61). The important role of
HMGA1 at these levels is supported by phenotypic studies in
Hmga1-knockout mice, indicating that mice lacking HMGA1
develop cardiomyopathy, aberrant hematopoiesis, and defective
pancreatic beta cell development (19, 62). Also, HMGA1
plays a role in adipogenesis, and myogenesis, although its
levels decrease before terminal cell differentiation (63, 64).
Vice versa, overexpression of HMGA1 is found in a wide
range of human cancers, including prostate, thyroid, colon,
breast, lung, bladder, pancreas, stomach, kidney, uterus, and
hepatocellular carcinomas, as well as non-melanoma skin
cancers, and hematopoietic malignancies (10, 14, 65, 66). In some
of these cancers, HMGA1 expression strongly correlates with an
advanced stage, the metastatic potential and reduced survival.
Poorer prognosis is due to the fact that HMGA1 promotes the
transcription of many genes involved in tumor growth, invasion,
migration, neoangiogenesis, epithelial-mesenchymal transition
and cancer metastasis (8, 10, 67–71). Nevertheless, it has been
also reported that HMGA1 can have anti-oncogenic effects,
depending on the cellular context (72). This bivalent function
proves the relevance of HMGA1 in both physiological and
pathological conditions and explains the reason why HMGA1
requires a fine-tuned spatio-temporal expression and activity
modulation.
DNA, Protein and RNA Interactions
HMGA1 regulates cell cycle-related chromosomal changes, DNA
replication and repair, and molecular chaperoning (11, 38,
73). Also, by inducing a more open chromatin state, HMGA1
assists gene transcription (8, 74). By itself, HMGA1 has no
intrinsic transcriptional activity; rather, it can participate in
the transactivation of gene promoters through mechanisms
that facilitate the assembly and stability of stereospecific DNA-
protein complexes, termed “enhanceosomes,” that drive gene
transcription (Figure 2) (75–77). HMGA1 performs this task
by interacting with a large variety of activating or inhibiting
transcription factors and orchestrating their assembly on
promoter regions. The enhanceosome model provides one of
the best-understood examples of how HMGA1 can interact with
other transcription factors, leading to a highly specific activation
of gene transcription in higher eukaryotes (76, 77). In this sense,
enhanceosome formation over the IFN-beta promoter (75, 77)
or the INSR promoter (15) is of paradigmatic importance. In
relation to protein-protein interactions, the HMGA1 network
has been reported to be very wide (78, 79), as HMGA1 has
been shown to physically and functionally interact with many
ubiquitous and tissue-specific transcription factors. Although
the repertoire is far for being complete, the interplays of
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HMGA1 with the transcription factors p53, NF-κB and ATF-
2/c-Jun, C/EBP beta and Sp1, as well as PDX-1 and MafA
have been studied in depth, being crucial, for example, in the
transcriptional regulation of Bcl 2 (80), IFN-beta (75), INSR
(15), and insulin (18) genes, respectively. Besides C/EBPbeta
and PDX-1, among the nuclear factors known to be involved in
glucose metabolism, HNF-1alpha has been shown to bind and
cooperate with HMGA1 in the regulation of the IGFBP1 and
IGFBP3 promoters (16), whereas the peroxisome proliferator-
activated receptor-gamma (PPARgamma), which reduces INSR
gene transcription, failed to show any direct interaction with
HMGA1 in this context (81). The potential interplay of HMGA1
with other nuclear metabolic sensors, such as ChREBP, SREBP1-
c, FoxO family members, and PGC-1, instead, has not yet been
investigated.
Emerging lines of evidence indicate that HMGA1 interacts
also with different RNAs. The first evidence supporting a specific
RNA affinity of HMGA1 has been reported in studies pointing to
a role of HMGA1 during the exon skipping of presenilin-2 pre-
mRNA, which resulted in the production of a deleterious protein
isoform causing sporadic Alzheimer’s disease (82). More recently,
a new interaction has been reported between HMGA1 and the
nuclear non-coding 7SK RNA (83), a factor which negatively
affects Polymerase II transcription elongation and influences
HMGA1 biological functions by competing for the first AT-
hook binding with DNA (84). Also, through the first AT-hook,
HMGA1 has been shown to interact with the origin recognition
complex, thus playing a key role in DNA replication (85).
HMGA1 AND GLUCOSE HOMEOSTASIS
HMGA1 in the Regulation of the INSR Gene
The peptide hormone insulin exerts its biological effects by
binding to the INSR, a specific tyrosine kinase receptor
glycoprotein located in the plasma membrane of insulin target
cells. As a key regulator of insulin action, many studies have
explored the INSR gene (86, 87). Nuclear binding proteins
that recognized the INSR promoter were initially identified
during muscle and adipose cell differentiation in the context
of two AT-rich sequences of the regulatory region of the INSR
gene (88). Using conventional chromatographic purification
methods, combined with electrophoretic mobility shift assays
and immunoblots, these proteins were identified as HMGA1,
while reporter gene analysis findings showed that HMGA1
is required for proper transcription of the INSR gene (89).
Further studies demonstrated that transcriptional activation of
the human INSR gene required the assembly of a transcriptionally
active multiprotein-DNA complex, including the ubiquitously
expressed transcription factor Sp1 and C/EBPbeta, in addition
to HMGA1 (15). As HMGA1 physically interacts with these
proteins and facilitates their binding to DNA, functional integrity
of this protein-DNA complex is necessary for full transactivation
of the INSR gene promoter by Sp1 and C/EBPbeta (15). In
support of the role of HMGA1 in INSR gene transcription,
in vitro investigations in beta-pancreatic cells demonstrated
that sustained hyperglycemia impaired HMGA1 expression, a
condition affecting INSR content in beta cells and, thus, insulin
secretion (90).
These observations, which were based mainly on in vitro
analyses, were substantiated by studies in vivo, in Hmga1-
knockout mice, in which a marked decrease in INSR gene
and protein expression was observed in the major targets of
insulin action, contributing to a phenotype characteristic of
human type 2 diabetes (19). Studies in patients with low INSR
as a consequence of defects in HMGA1 will be discussed
in the “HMGA1 in insulin resistant diseases” section, while
discrepancies between human and mouse phenotypes will be
discussed later.
Subsequent investigations revealed that other transcription
factors, such as the activating protein 2 (AP2) and PPARgamma,
can influence INSR gene transcription in a variety of cell types
(81, 91), while studies in cultured myocytes aimed at deciphering
the mechanisms by which free fatty acid (FFA) contribute to the
development of insulin resistance and type 2 diabetes, showed
that FFA can impair INSR expression and insulin signaling
and sensitivity by affecting HMGA1 (92–95). In particular, FFA
induce phosphorylation and nuclear translocation of the protein
kinase C epsilon type (PKCepsilon). In the nucleus, PKCepsilon
phosphorylates HMGA1 and downregulates its expression by
deactivating the transcription factor Sp1, thereby attenuating
INSR gene expression by direct and indirect mechanisms,
which in turn compromise insulin action and sensitivity (92–
95). Furthermore, recent studies addressed the mechanisms
linking the downregulation of the histone methyltransferase
G9a/EHMT2 with insulin resistance in murine models and in
cultured human hepatic cells. G9a/EHMT2 upregulates HMGA1
and G9a knockdown hepatic cells showed reduced INSRs,
whose expression was restored by overexpressing HMGA1 (32).
Importantly, restoration of G9a levels in db/db mice improved
hepatic insulin signaling and ameliorated hyperglycemia and
hyperinsulinemia at least in part by upregulating HMGA1 (32).
Altogether, these findings clearly indicate that HMGA1 is a
crucial component of the insulin signaling pathway, and plays an
important role in INSR gene expression in insulin target tissues.
HMGA1 in the Transcription of the Insulin
(INS) Gene
A direct role of HMGA1 in insulin production and pancreatic
islet development and beta cell function has been postulated
starting from the observation that, compared to wild-type
littermates, Hmga1-knockout mice showed decreased insulin
secretion and reduced beta cell mass (19). On the other hand,
a functional interplay between HMGA1 and the homeodomain
transcription factor PDX-1 (a key regulator of pancreatic islet
development and beta cell function) has been shown previously
in the context of the INS gene and other pancreatic islet-specific
genes (96). The possibility for HMGA1 to play a role also in
this context, was substantiated by the fact that binding of PDX-
1 to the INS gene promoter was reduced in Hmga1-knockout
mice (19). Also, a protein-protein interplay between PDX-1, the
neurogenic differentiation 1 (NeuroD1), and HMGA1 had been
previously described at the level of the rat insulin mini-enhancer
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FIGURE 2 | HMGA1 as facilitator of enhanceosome formation. HMGA1 binds to the enhancer region through its DNA-binding domain, while interacting with other
transcription factors in the promoter, forming a multiprotein-DNA complex that enhances gene transcription. The scheme refers to activation of the INSR gene.
element E2A3/4 (96). Subsequent studies added more details in
our understanding of the INS gene regulation. In the insulin-
secreting beta-cell line INS-1, as demonstrated by chromatin
immunoprecipitation experiments, glucose stimulated binding of
HMGA1 to the INS promoter, resulting in a significant increase
in insulin production and secretion (18). Coherently, when INS-
1 cells were treated with HMGA1 siRNA, a significant reduction
in glucose-induced insulin secretion was observed, thereby
confirming the importance of HMGA1 in this scenario (18). Even
in the absence of HMGA1-DNA binding sites on the INS gene
promoter, the assembly of a transcriptionally active multiprotein-
DNA complex involving HMGA1, PDX-1 and the transcription
factor MafA, was required for proper transcription of both
human and mouse INS genes (18). In line with this observation,
the deficit in HMGA1 compromised binding of PDX-1 andMafA
to the INS promoter, thereby imparing INS gene transcription
and glucose-induced insulin secretion (18). However, given
that substantial interspecies differences exist in pancreatic islet
development and function (19, 97, 98), any parallelism between
human and mouse at this level must be considered carefully and
further details on this should be provided. For example, based
on our recent observations highlighting a novel relationship
between HMGA1 and FoxO1 (99), further investigation in this
field could deliver deeper information on the possibility that an
interplay among HMGA1 and FoxO1 can be a component of this
regulation, as an overarching role of FoxO1 in pancreatic beta cell
function has been already outlined (6, 100–103).
HMGA1 as a Downstream Target of the
INSR Signaling Pathway
Besides being required for both insulin and INSR gene
transcription, HMGA1 plays an important role in the regulation
of the insulin signaling cascade (98). The gluconeogenic genes
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (G6Pase), as well as the IGFBP1 gene (which plays
a glucose counterregulatory role by preventing the potential
hypoglycemic effects of IGF1) are known to be inhibited by
insulin (for example, after a meal). As reported in vitro, in hepatic
cells, insulin, via the phosphatidylinositol 3-kinase (PI-3K)/Akt
pathway, and the Akt/protein kinase CK2 signaling, exerts its
transcriptional repression of these genes by inducing HMGA1
phosphorylation (104). In fact, by triggering the phosphorylation
of HMGA1 at the level of the three serine residues, Ser-98, Ser-
101, and Ser-102, insulin promotes the detachment of HMGA1
from promoter target genes and its corresponding nuclear
localization in the inactive heterochromatin. Thus, HMGA1 acts
as a downstreammodulator of insulin action, and is an important
key player in insulin and nutritionally-regulated transcription
of genes involved in glucose metabolism and homeostasis. Also,
as phosphorylation/dephosphorylation of HMGA1 can act as
a molecular switch for deactivating or activating INSR protein
expression during fed and fasting conditions, respectively (104),
HMGA1 can function as a key feedback regulator of insulin
signaling during the fasting and refeeding periods.
Given that the role of the transcription factor FoxO1 in the
control of gluconeogenesis is well established (6, 105), as for the
regulation of pancreatic beta cell function, a cross-talk between
HMGA1 and FoxO1 can be hypothesized also in this case and
investigated in future studies.
HMGA1 and Insulin-Independent Metabolic
Signaling
Data from the Hmga1-knockout mouse model evidenced a
complex metabolic phenotype, in which peripheral insulin
hypersensitivity paradoxically coexisted with a condition
of impaired glucose tolerance and overt diabetes (19), thus
supporting the existence of alternative insulin signaling
pathways ensuring peripheral glucose utilization and disposal
by insulin-independent mechanisms. Coexistence of insulin
hypersensitivity in peripheral tissues with insulin resistance
has been observed before in liver of ob/ob mice (106) and
in Cdk4 knockout mice with defects in pancreatic beta cell
development and insulin secretion (107). The possibility that
the activation of insulin-independent mechanisms aimed at
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ameliorating glucose disposal under disadvantageous metabolic
conditions, like those affecting Hmga1-knockout animals, is
underlined by the identification of novel biochemical pathways
involving the cAMP-HMGA1-RBP4 system (17, 108) and the
HMGA1-IGF1/IGFBP system (16), whose activation may play
a role in glucose homeostasis in both rodents and humans.
Further studies in vitro confirmed that HMGA1 has a role in
the activation of both IGFBP1 and IGFBP3 gene transcription
(16, 109). Therefore, it is plausible that under physiological
circumstances (e.g., during fasting), in which HMGA1 increases
(17, 108), the increment of both IGFBP1 and IGFBP3 helps
in limiting IGF1 bioavailability, thereby preventing peripheral
glucose uptake by insulin-independent mechanisms.
Role of HMGA1 During Fasting
The counter-regulatory hormone glucagon, which acts
in opposition to insulin, binds its cognate G-protein
coupled receptor on liver cell membrane and stimulates the
transmembrane adenylyl cyclase to produce cyclic AMP (cAMP)
as second messenger. This, in turn, leads to the activation of
protein kinase A (PKA), which, among many other proteins,
phosphorylates the Cyclic AMP Responsive Elements Binding
Protein (CREB) transcription factor (110, 111). The final event
is the assembly of a functional transcriptional machinery on
the promoter regions of gluconeogenic genes (112). Some
observations in cultured hepatic cells indicate that cAMP also
increases HMGA1 protein expression (17, 108). Consistently,
Hmga1 RNA levels were significantly increased in liver of mice
following systemic administration of glucagon.
In agreement with the observations mentioned above,
upregulation of FoxO1 expression via the glucagon-cAMP-PKA
signaling has been reported in liver of fasting mice to maintain
fasting euglycemia (113). Thus, upregulation of HMGA1 during
fasting (when glucagon peaks) may contribute to themechanisms
necessary to prevent hypoglycemia, through activation of FoxO1
(99) and gluconeogenic gene expression. The opposite occurs
after a meal, when insulin peaks, and glucagon declines
(Figure 3). In this metabolic scenario, inactivation of HMGA1
by insulin-induced HMGA1 phosphorylation, by causing the
detachment of FoxO1 from DNA and its nuclear exclusion,
inhibits gluconeogenesis and contributes to restoration of
postprandial euglycemia (Figure 3).
Kidney exerts an important role in gluconeogenesis, being
responsible of approximately 15% of glucose production (1). In a
recent paper, after 3-day fasting or restriction diet in mice, renal
gene expression, assayed by microarray, demonstrated, among
other transcription factors, an increment in HMGA1 expression
(114). These findings are coherent with previous findings in the
liver, in which an effect of HMGA1 on gluconeogenic genes has
been described (104).
Another glucose metabolism-related gene, which has been
shown to be regulated by HMGA1, is the one encoding for the
retinol binding protein 4 (RBP-4). RBP-4 is mostly produced
by the liver, although adipose tissue also contributes, and
plays a role in systemic insulin resistance. RBP-4 expression
in fat and its levels in blood inversely correlated with the
adipose-specific glucose transporter GLUT-4 in obesity and
type 2 diabetes (115). In vitro studies with human HepG2
and murine Hepa 1 hepatoma cells have demonstrated that
HMGA1 binds to and increases transcription of the RBP-4 gene
promoter both in basal and in cAMP-induced conditions (17,
108), while in vivo, in whole mice, injection of glucagon, by
inducing increased intracellular cAMP, activates both HMGA1
and RBP-4 expression in liver and fat. Consequently, under
physiological circumstances, this loop has an important relapse
in conditions of low glucose availability, in which intracellular
cAMP increases. In this scenario, HMGA1, by inducing FoxO1-
dependent gluconeogenic genes, and by upregulating RBP-4,
helps providing glucose to tissues/organs with high energy
demands, such as the brain. Interestingly, the brain-type GLUT-
3 facilitative glucose transporter has also been shown to be
transcriptionally regulated by HMGA1 (116), thereby supporting
further the relevance of this factor in multiple settings of energy
demand.
HMGA1 in Adipose and Muscle Cell
Differentiation and Function
Both muscle and fat play relevant roles in maintaining
euglycemia. In this regard, previous studies from our group
demonstrated that INSR expression is reduced in muscle
and adipose tissues from both Hmga1-knockout mice and in
individuals with reduced levels of HMGA1 (19, 44).
The physiological role of HMGA1 in adipogenesis has been
investigated in vitro and in vivo (63, 117), and a critical role
of HMGA1 in adipocytic cell growth and differentiation has
been demonstrated in murine 3T3-L1 adipocytes (117). Also,
HMGA1 may exert a negative role in adipose cell growth by
balancing the effects of the cognate HMGA2 protein, another
member of the HMGA family (118). Indeed, transgenic mice,
overexpressingHMGA1 in both white and brown adipose tissues,
showed reduced fat mass and impaired adipogenesis with respect
to wild-type mice (63), and were protected against high-fat diet
induced obesity and systemic insulin resistance, thus supporting
the role of HMGA1 in the maintenance of glucose homeostasis.
In addition to RBP-4, whose regulation has been discussed,
other adipokines have been demonstrated to be under the control
of HMGA1. In 3T3-L1 adipocytes, visfatin, an insulin-mimetic
factor, is transcriptionally regulated by HMGA1 in cooperation
with the hypoxia-inducible factor 1, HIF-1 (119), whereas leptin,
an adipokine involved in glucose and fatty acid metabolism,
is regulated by HMGA1 through a non-canonical mechanism
that spares HMGA1 direct binding to DNA and requires the
physical interaction and functional cooperation of HMGA1 with
the nuclear factor C/EBPbeta (117).
Several reports have also indicated that HMGA1 plays
a role in muscle tissue, and HMGA1 is present in mouse
C2C12 cultured muscle cells, in which HMGA1 overexpression
increases cell proliferation and prevents myotube formation (64).
Downregulation of HMGA1 is an early and necessary step for
the progression of the myogenic program. In this regard, it
has been reported that miR-195/497, by binding the HMGA1
3′UTR, reduces HMGA1 protein abundance in C2C12 cells, thus
promoting muscle cell differentiation (120).
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FIGURE 3 | Hypothetical mechanisms underlying the effects of HMGA1/FoxO1 on glucose homeostasis. The increase of glucagon during fasting (Left) turns on the
cAMP-PKA-CREB pathway, allowing HMGA1 gene activation and protein expression. In turn, HMGA1 activates the FoxO1 gene and promotes transactivation of
G6Pase and IGFBP1 promoters by FoxO1, thereby maintaining fasting euglycemia through elevation of hepatic gluconeogenesis and attenuation of IGF1 bioactivity.
Under feeding conditions (Right), binding of insulin to its receptor initiates a series of events culminating in the sequential phosphorylation (p) of HMGA1 and FoxO1,
which reduces FoxO1 gene expression, promotes the detachment of FoxO1 from G6Pase and IGFBP1 gene promoters, and leads to FoxO1 nuclear exclusion,
thereby ensuring postprandial euglycemia through inhibition of hepatic gluconeogenesis and augmentation of IGF1 bioactivity.
The Lin28/let-7 pathway, whose implication in cancer is well
known (121), displays also a role in the regulation of glucose
metabolism. In fact, mice overexpressing Lin28a and Lin28b
show an insulin-sensitized state, with protection against high-fat
diet induced diabetes (122). In contrast, muscle-specific loss of
Lin28a and overexpression of let-7 resulted in insulin resistance
and impaired glucose tolerance (122). As Lin28a directly
promotes HMGA1 translation (123), it has been postulated that
in muscle-specific Lin28a knockout mice, insulin resistance is, at
least in part, due to reduced HMGA1 levels and consequently
impaired INSR expression (122). If confirmed in further studies,
the relationship between HMGA1 and the Lin28/let-7 pathway
may indicate another molecular mechanism for the involvement
of HMGA1 in mammalian glucose metabolism.
HMGA1 IN INSULIN RESISTANT DISEASES
Syndromes of Severe Insulin Resistance
Insulin resistance, defined as a subnormal biological response to
the glucose-lowering effect of insulin, is a characteristic of many
common disorders, including type 2 diabetes, the metabolic
syndrome, fatty liver disease, and obesity (124–126). However,
severe forms of insulin resistance may occur as uncommon
syndromes, either congenital or acquired, in patients with
impaired INSR signaling or lipodistrophy (127, 128). Congenital
disorders include the Type A syndrome of insulin resistance,
the Rabson-Mendenhall syndrome, leprechaunism, and some
syndromes of generalized or partial lipodystrophy. Type A
syndrome is an autosomal dominant disorder characterized
by the triad of hyperinsulinemia, acanthosis nigricans, and
ovarian hyperandrogenism (127–129). Hyperglycemia is not
always present at diagnosis. Female patients appear lean and
without lipodystrophy, even if a variant of this syndrome has
been reported in obese women (130, 131). Male patients may
initially exhibit acanthosis nigricans and hypoglycemia, while
overt diabetes may not occur until the fourth decade or later
(128). In some cases, the syndrome is caused by heterozygous
mutations affecting the tyrosine kinase domain of the INSR;
however, only 10–25% of female with Type A syndrome have
mutations in the INSR gene (132).
As a step toward understanding the molecular basis of
regulation of the INSR gene, a nuclear binding protein that
specifically interacted with, and activated the INSR gene
promoter, was identified previously, during muscle and adipose
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cell differentiation (88). Later, this DNA binding protein was
identified as HMGA1, and its expression was markedly reduced
in two unrelated patients with either the Type A syndrome
or the common form of type 2 diabetes, in whom cell surface
INSRs were decreased and INSR gene transcription was impaired
despite the fact that the INSR genes were normal, thus indicating
defects in INSR gene regulation (15, 89, 133). Subsequent
investigations in both these patients allowed the identification of
a novel genetic variant, c.∗369del, in the 3′ non-coding region
of HMGA1 mRNA, which resulted in a decreased mRNA half-
life and reduced HMGA1 protein levels. In other two patients
(mother and daughter) with the type A syndrome of insulin
resistance, a hemizygous deletion of the HMGA1 gene was
also identified (19). Restoration of HMGA1 protein expression
in these subjects’ cells enhanced INSR gene transcription and
restored cell-surface INSR protein expression, thus confirming
that defects in HMGA1, by decreasing INSR protein production
may indeed induce severe insulin resistance (19).
The mechanistic linkage between HMGA1, insulin resistance
and certain less common forms of type 2 diabetes has been
further supported by a study in two diabetic patients, in whom
aberrant expression of a pseudogene for HMGA1, HMGA1-p,
caused destabilization of HMGA1 mRNA with consequent loss
of INSR and generation of insulin resistance (44).
These findings demonstrate, therefore, that HMGAl is
necessary for proper expression of the INSR. Further, they
provide evidence for recognizing “HMGA1opathy” as a novel
diabetic subphenotype (134).
Type 2 Diabetes
In its common form, type 2 diabetes is a heterogeneous
complex disease in which concomitant insulin resistance and
beta-cell dysfunction lead to hyperglycemia (135, 136). From a
pathogenetic point of view, both predisposing genetic factors and
precipitating environmental factors contribute importantly to the
development of the disease (135, 136). So far, about 100 gene
variants have been associated with an increased risk for type 2
diabetes (137). Most of these variants are presumed to negatively
affect pancreatic beta-cell function and insulin secretion, while
some of them appear to impact peripheral insulin sensitivity,
thereby impairing tissue glucose uptake (138).
As it concerns HMGA1, on the basis of its involvement
in insulin resistance, a role for this nuclear factor in type 2
diabetes has also been postulated and studies in this direction
have been performed by us and others (20, 139–141). In
particular, by sequencing the entire HMGA1 gene in a large
number of diabetic patients and healthy controls, four variants
of the HMGA1 gene were identified by us in approximately
10% of diabetics (20). In circulating monocytes and cultured
lymphoblasts from diabetic patients carrying these variants,
HMGA1 and INSR expressions were markedly decreased and
these defects were corrected by transfecting HMGA1 cDNA (20).
The most frequent HMGA1 rs139876191 variant (previously
named rs146052672), was significantly higher in type 2 diabetic
patients from three populations of white European ancestry:
Italian, American and French populations (20). Although not
replicated in a heterogeneous French population (139), the
rs139876191 variant was later associated with type 2 diabetes
among Chinese (140) and Americans of Hispanic ancestry (141),
thus providing evidence for the implication of the HMGA1 gene
locus as one conferring a cross-race risk for the development of
type 2 diabetes. More recently, the credibility of an association
between the HMGA1 rs139876191 variant and type 2 diabetes
was confirmed also in a transethnic meta-analysis that included
all available published articles examining this association in
different populations (142). Like other polymorphisms located at
the intron/exon boundaries, functional analysis of the HMGA1
rs139876191 revealed that this variant is functional and exhibits
a dominant negative effect (143).
Metabolic Syndrome
Themetabolic syndrome is a commonmulticomponent disorder,
which is associated with increased risk for type 2 diabetes,
cardiovascular disease (CVD), and nonalcoholic fatty liver
disease (144, 145). As insulin resistance plays a pivotal role
in the pathophysiology of metabolic syndrome (125, 146), the
impact of HMGA1 has been investigated in two large Italian
and Turkish populations, both affected by metabolic syndrome
(21). Findings indicated that the HMGA1 rs139876191 variant
was significantly associated with metabolic syndrome in both
populations, in which this association occurred independently
of type 2 diabetes, thus lending credence to the hypothesis
that this variant may independently associate with other insulin
resistance-related traits. Consistent with this assumption, a
strong association of the rs139876191 variant with certain
metabolic syndrome-related traits (i.e., high fasting plasma
glucose, high body mass index, low HDL-Cholesterol, reduced
insulin sensitivity) was observed in affected individuals of
European and Hispanic-American ancestry, further supporting
the notion that defects that negatively affect HMGA1 can play
a role in the pathogenesis of metabolic syndrome and other
insulin-resistance related conditions (21, 141). Interestingly, as
CVD is a major risk for both type 2 diabetes and the metabolic
syndrome, the association of HMGA1 rs139876191 variant with
acute myocardial infarction, independently from diabetes and
other cardiovascular risk factors, has been reported previously
(147, 148), suggesting that HMGA1 may also represent a novel
genetic marker of cardiovascular risk.
Discrepancy Between Human and Mouse
Phenotypes With HMGA1 Loss-of-Function
An important issue that deserves to be discussed is to which
extent Hmga1-knockout mice reflect findings in humans.
Although in the broader context of glucose metabolism
similarities between the two species are well known (i.e., in
both species, insulin and glucagon represent key effectors in
the control of glucose homeostasis), differences are likewise
described in relation to pancreas development and, in particular,
to the late stages of beta cell differentiation and susceptibility
to pancreatic beta-cell injury (97, 149, 150). At a molecular
level, previous known beta cell species-specificities in ion channel
components and membrane transporters, as well as in insulin
secretion, have been recently further enriched by data from
transcriptome profiles in single human and murine beta cells
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(150, 151), while evidence of heterogeneity of pancreatic beta
cells has been proved to occur in both humans and mice (152).
However, interspecies differences do not exclude that in some
instances, like in the case of lack of the KCNJ11 gene, the mouse
phenotype well recapitulates human neonatal diabetes (153).
Focusing on HMGA1 loss-of-function, three biochemical
and metabolic conditions are common to humans and mice:
reduced insulin receptor expression, impaired insulin signaling,
and insulin resistant diabetes. Instead, insulin levels in humans
(hyperinsulinemic) and mice (hypoinsulinemic) are clearly
discrepant (19). In fact, in Hmga1-knockout mice, both beta
cell mass and insulin secretion are impaired. Differences
in pancreatic islet ontogenesis and differentiation, as well
as differences in nongenetic environmental elements and
susceptibility to genetic modifiers, have been postulated to
explain these dissimilarities (19). On the other hand, Hmga1-
knockout mice have proved to be insulin hypersensitive, despite
the deficit in INSRs. This apparent paradox suggests the presence
of adaptive, compensatory mechanisms, in mice, that include
the already described cAMP-HMGA1-RBP4 pathway and the
IGFBP-1/IGF1 system. Although the latter has proved to be
more effective to reduce glycemia in mice than in humans
(154), the importance of these systems in both species still
deserves further investigations. As an example, recent findings
obtained in genetically engineered mice with a specific deletion
of the RBP4 gene in the liver, indicating that circulating RBP4
derives mainly from hepatocytes (155), need to be confirmed in
humans.
CONCLUSIONS
At present, HMGA1 is known to be involved in multiple
biological processes. Based on the above-mentioned findings,
among the many tasks that HMGA1 can perform, there is its
role in the transcriptional regulation of gene and gene networks
involved in INSR signaling and glucose metabolism. In this
review, we provided an overview of the major contributions that
have been made in this area over the last years. Overall, the data
obtained so far well support the role of HMGA1 in the regulation
of genes implicated in the maintenance of glucose homeostasis
and metabolic control, providing new insight into the regulation
of glucose metabolism and disposal. Clinically, the importance
of HMGA1 gene variability in glucose metabolism is emphasized
in a wide range of clinical conditions ranging from rare insulin
resistance syndromes to type 2 diabetes and the metabolic
syndrome. Besides, being a multifunctional protein, HMGA1
may constitute a molecular link between metabolism and other
distinct biological processes, including cell proliferation, and
differentiation, viability, autophagy, cell cycle, apoptosis, that
need to be sustained by cell energy.
New insights may come from epigenetic studies, including
miRNAs, whose common role in both malignancy and
metabolism is recently emerging. On the other hand,
disentangling the pleiotropic nature of HMGA1 by the
identification of distinct molecular partners and networks
uniquely implicated in metabolism, still represents a big
challenge. A contribution could come from studies on the
relationship between HMGA1 and the yet unexplored nuclear
metabolic sensors.
Apart from the intrinsic biological and clinical interest of these
findings, a deeper understanding of the mechanisms that regulate
glucose metabolism in health and disease is of importance for the
development of more effective therapies. To fill the gap of our
knowledge in this regard, future directions based on the omics-
related technologies, combined with bioinformatic tools, can help
identify novel proteins and their networks, as well as genes and
gene products regulated by, or interacting with HMGA1.
To the best of our knowledge, this is the first review article
exclusively dedicated to the role of HMGA1 in this context, and
we hope that it will serve as a quickly accessible reference in this
important clinical field.
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